��ɫ��

��ɫ��

Donate To Research Join The AAN

Events

Resources For

Abstract Details

Title Dynamics of Th17 Cells during and after Cessation of Natalizumab Therapy

Topic Multiple Sclerosis

Presentation(s) (-)

Poster/Presentation
Number 277

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
Brigitte Wildemann, MD (University Hospital Heidelberg, Department of Neurology) PRESENTER	The institution of Dr. Wildemann has received research support from Roche. The institution of Dr. Wildemann has received research support from Novartis. The institution of Dr. Wildemann has received research support from Argenx. Dr. Wildemann has received personal compensation in the range of $500-$4,999 for serving as a Conference participant with Neuraxpharm. Dr. Wildemann has received personal compensation in the range of $0-$499 for serving as a Speaker with Roche. Dr. Wildemann has received personal compensation in the range of $0-$499 for serving as a Soeaker with Instand.
	No disclosure on file
Mirjam Korporal-Kuhnke, MD	Dr. Korporal-Kuhnke has nothing to disclose.
	No disclosure on file